721 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Purchased by Investidor Profissional Gestao de Recursos Ltda.

Investidor Profissional Gestao de Recursos Ltda. acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 721 shares of the company’s stock, valued at approximately $240,000. Medpace accounts for approximately 0.1% of Investidor Profissional Gestao de Recursos Ltda.’s portfolio, making the stock its 15th biggest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. R Squared Ltd acquired a new position in shares of Medpace in the fourth quarter worth $30,000. SBI Securities Co. Ltd. acquired a new position in Medpace in the 4th quarter worth about $31,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several recent research reports. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective on the stock. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a report on Monday, March 24th. Finally, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Stock Down 5.6 %

Shares of NASDAQ:MEDP opened at $287.11 on Friday. The business has a 50 day moving average price of $331.56 and a 200 day moving average price of $337.60. The company has a market cap of $8.75 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45. Medpace Holdings, Inc. has a twelve month low of $282.42 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.